DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Phase 2

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: NIS793
Drug: Bevacizumab
Drug: Modified FOLFOX6
Drug: FOLFIRI
Drug: Tislelizumab

First Posted Date: 2021-07-07

Last Posted Date: 2025-03-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 204

Registration Number: NCT04952753

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
University of Michigan Medical, Ann Arbor, Michigan, United States
🇺🇸
WA Uni School Of Med, Saint Louis, Missouri, United States

and more 5 locations

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Phase 3

Active, not recruiting

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: ABL001 40mg BID
Drug: ABL001 80mg QD
Drug: ABL001 200mg QD

First Posted Date: 2021-07-01

Last Posted Date: 2025-04-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 199

Registration Number: NCT04948333

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: CSJ117
Drug: Placebo

First Posted Date: 2021-06-30

Last Posted Date: 2022-10-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 136

Registration Number: NCT04946318

Locations: 🇸🇰
Novartis Investigative Site, Levice, Slovakia

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Completed

Conditions: Somatostatin Receptor-positive GEP-NET

Interventions: Other: Lutathera

First Posted Date: 2021-06-30

Last Posted Date: 2024-08-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 89

Registration Number: NCT04946305

Locations: 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of

A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia

Recruiting

Conditions: Breast Cancer

Interventions: Other: ribociclib
Other: mono endocrine therapy
Other: aplelicib
Other: chemotherapy

First Posted Date: 2021-06-29

Last Posted Date: 2025-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3290

Registration Number: NCT04943497

Locations: 🇷🇺
Novartis Investigative Site, Voronezh, Russian Federation

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: 68Ga-FAP-2286
Drug: 177Lu-FAP-2286

First Posted Date: 2021-06-25

Last Posted Date: 2025-05-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 222

Registration Number: NCT04939610

Locations: 🇺🇸
Hoag Hospital Irvine, Irvine, California, United States
🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
UCSF Medical Center, San Francisco, California, United States

and more 6 locations

Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer

Phase 3

Active, not recruiting

Conditions: Differentiated Thyroid Cancer

Interventions: Drug: Dabrafenib
Drug: Trametinib placebo
Drug: Dabrafenib placebo
Drug: Trametinib

First Posted Date: 2021-06-25

Last Posted Date: 2025-05-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 153

Registration Number: NCT04940052

Locations: 🇺🇸
Northwestern University Med School, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

Completed

Conditions: Active Secondary Progressive Multiple Sclerosis
Relapsing-remitting Multiple Sclerosis

Interventions: Other: Kesimpta

First Posted Date: 2021-06-25

Last Posted Date: 2025-01-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 367

Registration Number: NCT04940065

Locations: 🇯🇵
Novartis Investigative Site, Wakayama, Japan

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

Phase 3

Completed

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: Drug: NIS793
Drug: Nab-paclitaxel
Drug: Gemcitabine
Drug: Placebo

First Posted Date: 2021-06-23

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 511

Registration Number: NCT04935359

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸
Advent Health Cancer Institute, Orlando, Florida, United States

and more 7 locations

Russian Registry of Patients With nAMD

Terminated

Conditions: Neovascular Age-Related Macular Degeneration

Interventions: Other: nAMD

First Posted Date: 2021-06-23

Last Posted Date: 2023-01-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2665

Registration Number: NCT04935411

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy